DeepMed Research

British Columbia Cancer Agency

Country

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer

Phase 2

Withdrawn

Conditions: Post-menopausal ER+ Stage I-IIIA Primary Operable Breast Cancer

Interventions: Drug: Aromatase Inhibitor
Drug: Abiraterone Acetate
Drug: Prednisone

First Posted Date: 2013-03-20

Last Posted Date: 2013-12-20

Lead Sponsor: British Columbia Cancer Agency

Registration Number: NCT01814865

Locations: 🇨🇦
BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada
🇨🇦
The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
🇨🇦
Segal Cancer Centre, Montreal, Quebec, Canada

and more 1 locations

Utilization of Genomic Information to Augment Chemotherapy Decision-making for People With Incurable Malignancies

Not Applicable

Completed

Conditions: Advanced Incurable Cancers

Interventions: Genetic: in depth genomic sequencing

First Posted Date: 2013-03-04

Last Posted Date: 2015-02-05

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 100

Registration Number: NCT01802905

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

HRV Biofeedback for Brain Tumour Survivors

Not Applicable

Suspended

Conditions: Anxiety
Sleep Impairment
Depression

Interventions: Behavioral: heart rate variability biofeedback

First Posted Date: 2013-01-21

Last Posted Date: 2015-05-06

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 15

Registration Number: NCT01772498

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

18F-FDG PET Imaging in Cardiac Sarcoidosis

Conditions: Cardiac Sarcoidosis

First Posted Date: 2013-01-09

Last Posted Date: 2022-02-04

Lead Sponsor: British Columbia Cancer Agency

Registration Number: NCT01764191

Locations: 🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos

Conditions: Mesothelioma
Lung Cancer

First Posted Date: 2012-11-01

Last Posted Date: 2012-11-01

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 200

Registration Number: NCT01719068

Locations: 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

Phase 2

Conditions: Prostate Neoplasm

Interventions: Drug: Degarelix

First Posted Date: 2012-06-28

Last Posted Date: 2012-06-28

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 40

Registration Number: NCT01630967

Locations: 🇨🇦
British Columbia Cancer Agency, Vancouver, British Columbia, Canada

Polarized Reflectance Spectroscopy for Oral Lesions

Phase 1

Completed

Conditions: Oral Cancer

Interventions: Device: Polarized Reflectance Spectroscopy System

First Posted Date: 2012-05-24

Last Posted Date: 2017-01-31

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 40

Registration Number: NCT01604759

Locations: 🇨🇦
British Columbia Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada

High Dose Rate Prostate Brachytherapy: Dose Escalation to Dominant Intra-prostatic Nodule

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Radiation: HDR interstitial brachytherapy

First Posted Date: 2012-05-24

Last Posted Date: 2021-07-21

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 26

Registration Number: NCT01605097

Locations: 🇨🇦
Cancer Center for the Southern Interior, Kelowna, British Columbia, Canada

Long Term Outcomes of Breast Intensity-Modulated Radiation Therapy

Conditions: Breast Cancer

First Posted Date: 2012-02-23

Last Posted Date: 2012-03-09

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 314

Registration Number: NCT01537406

Locations: 🇨🇦
BCCA - Vancouver Island Cancer Centre, Victoria, British Columbia, Canada
🇨🇦
Odette Cancer Centre, Toronto, Ontario, Canada

Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2011-10-05

Last Posted Date: 2020-01-27

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 50

Registration Number: NCT01446991

Locations: 🇨🇦
Abbottsford Cancer Center, Abbottsford, British Columbia, Canada
🇨🇦
Fraser Valley Cancer Center, Surrey, British Columbia, Canada
🇨🇦
Vancouver Cancer Center, Vancouver, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy